A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis.
Breast cancer
Cell Biology
Oncology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
22 09 2023
22 09 2023
Historique:
received:
04
08
2022
accepted:
15
08
2023
medline:
25
9
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Patients with triple-negative breast cancer remain at risk for metastatic disease despite treatment. The acquisition of chemoresistance is a major cause of tumor relapse and death, but the mechanisms are far from understood. We have demonstrated that breast cancer cells (BCCs) can engulf mesenchymal stem/stromal cells (MSCs), leading to enhanced dissemination. Here, we show that clinical samples of primary invasive carcinoma and chemoresistant breast cancer metastasis contain a unique hybrid cancer cell population coexpressing pancytokeratin and the MSC marker fibroblast activation protein-α. We show that hybrid cells form in primary tumors and that they promote breast cancer metastasis and chemoresistance. Using single-cell microfluidics and in vivo models, we found that there are polyploid senescent cells within the hybrid cell population that contribute to metastatic dissemination. Our data reveal that Wnt Family Member 5A (WNT5A) plays a crucial role in supporting the chemoresistance properties of hybrid cells. Furthermore, we identified that WNT5A mediates hybrid cell formation through a phagocytosis-like mechanism that requires BCC-derived IL-6 and MSC-derived C-C Motif Chemokine Ligand 2. These findings reveal hybrid cell formation as a mechanism of chemoresistance and suggest that interrupting this mechanism may be a strategy in overcoming breast cancer drug resistance.
Identifiants
pubmed: 37607007
pii: 164216
doi: 10.1172/jci.insight.164216
pmc: PMC10561721
doi:
pii:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA125577
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA107469
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Références
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Cell. 2015 May 21;161(5):1202-1214
pubmed: 26000488
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
pubmed: 17438091
Biomed Pharmacother. 2019 Jun;114:108800
pubmed: 30921705
Stem Cells. 2016 Apr;34(4):1011-26
pubmed: 26676563
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12072-7
pubmed: 11593017
Stem Cell Res Ther. 2021 Oct 18;12(1):544
pubmed: 34663475
Oncotarget. 2016 Jun 21;7(25):37790-37802
pubmed: 27191257
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
PLoS One. 2010 Feb 12;5(2):e9188
pubmed: 20169192
Stem Cell Res Ther. 2017 Jul 27;8(1):177
pubmed: 28750689
Cancer Res. 2011 Mar 15;71(6):2360-70
pubmed: 21406404
Cancer Res. 2012 May 1;72(9):2251-61
pubmed: 22422937
J Biomed Opt. 2012 Sep;17(9):96001
pubmed: 22975677
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Breast. 2016 Dec;30:92-100
pubmed: 27668856
EMBO J. 2010 Jan 6;29(1):41-54
pubmed: 19910923
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103
pubmed: 24516139
Drug Resist Updat. 2012 Feb-Apr;15(1-2):123-31
pubmed: 22365330
Cancer Chemother Pharmacol. 2021 Feb;87(2):147-158
pubmed: 33420940
FEBS J. 2020 Jul;287(13):2636-2646
pubmed: 32145148
Cell Rep. 2017 Jan 31;18(5):1215-1228
pubmed: 28147276
Aging Cell. 2016 Jun;15(3):428-35
pubmed: 26711051
Semin Cancer Biol. 2022 Jun;81:37-47
pubmed: 33358748
Sci Rep. 2015 Sep 08;5:13744
pubmed: 26345302
Biomed Pharmacother. 2006 Nov;60(9):548-56
pubmed: 16950593
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
pubmed: 7568133
Front Cell Dev Biol. 2021 Mar 29;9:645593
pubmed: 33855023
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6447-E6456
pubmed: 27698134
Mech Ageing Dev. 2009 Jan-Feb;130(1-2):24-32
pubmed: 18538372
Oncogene. 1999 Aug 26;18(34):4808-18
pubmed: 10490814
Cell Rep. 2019 Jun 25;27(13):3916-3926.e5
pubmed: 31242423
Biomed Res Int. 2014;2014:532161
pubmed: 25140317
Oncogene. 2017 Apr 20;36(16):2275-2285
pubmed: 27819674
Nat Commun. 2020 Apr 7;11(1):1723
pubmed: 32265444
Cell Adh Migr. 2012 May-Jun;6(3):220-30
pubmed: 22863739
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Oncogene. 2005 Jul 14;24(30):4765-77
pubmed: 15870702
Tumour Biol. 2015 Feb;36(2):973-81
pubmed: 25318604
Biomolecules. 2019 Nov 27;9(12):
pubmed: 31783552
Nature. 2022 Jun;606(7913):396-405
pubmed: 35650435